Please login to the form below

Not currently logged in
Email:
Password:

EUSA Pharma appoints Lee Morley as its new chief executive

UK specialty pharmaceutical company also adds Göran Ando to its board
Lee Morley

EUSA Pharma has appointed Lee Morley to be its new chief executive officer, taking over from Bryan Morton who becomes the UK specialty pharmaceutical company's executive chairman.

Morton originally founded EUSA in 2005, leading it until its 2012 acquisition by Jazz Pharmaceuticals for $700m and then taking the reins again last month when EUSA was once again launched as a new business with five specialty hospital products from Jazz.

EUSA's new CEO Morley comes to the company from Jazz, where he was vice president, head of commercial for Europe and International Markets, with responsibility for the original EUSA Pharma business.

Prior to his time with Jazz, and before that the pre-acquisition EUSA business, Morley was director of sales effectiveness at specialty oncology and critical care company Zeneus Pharma.

Before that he held a number of sales and marketing management positions at Merck, Sharp and Dohme, including UK National Sales Manager.

Meanwhile, EUSA has also added industry veteran and Novo Nordisk chairman Dr Göran Ando to its board of directors.

Commenting on the appointments Bryan Morton said: “We are delighted to welcome both Lee and Göran to EUSA Pharma during this exciting time in the development of the company.

“We have highly ambitious growth plans to build EUSA into a world-class specialty pharma business through acquisition and in-licensing, and Lee's extensive commercial experience will prove invaluable in helping us achieve our goal. We also welcome the strategic insight and direction Göran will provide as we transform the business.”

24th April 2015

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...